Download our whitepaper,
Navigating the Complexities of
HIV/AIDS Clinical Trials: Diagnosis,
Endpoints, and Regulatory
Pathways
What's Inside:
- Key FDA-Approved Pivotal Endpoints for HIV/AIDS Clinical Trials.
- Optimizing Recruitment with Adaptive Trial Designs for HIV/AIDS.
- Comprehensive Analysis of FDA-Approved HIV/AIDS Drugs.
- How Diagnostic Criteria for HIV/AIDS Have Evolved and Impact Research.
- Overcoming Common Pitfalls in HIV/AIDS Clinical Trials.
- And additional insights to drive your trial’s success.
Access your complimentary whitepaper today:
HIV/AIDS
HIV/AIDS is a serious and life-altering condition that impacts the immune system, leaving the body vulnerable to infections and diseases. Without treatment, it can lead to significant health complications, including opportunistic infections, cancer, and organ damage, ultimately resulting in death. Advances in medicine, however, have made HIV a manageable chronic condition for many individuals.
The molecular understanding of HIV has enabled the development of targeted antiretroviral therapies (ART). These treatments suppress the virus, reduce the risk of transmission, and allow individuals to lead healthier lives. By addressing the virus at the cellular level, these therapies have transformed HIV from a fatal diagnosis to a manageable condition with a near-normal life expectancy.
At iNGENū, our team of researchers and clinicians is committed to advancing the science of HIV/AIDS. Through groundbreaking research, innovative trial designs, and a focus on patients’ needs, we aim to accelerate the development of next-generation treatments, improve accessibility, and work toward a future free from HIV/AIDS.
1 in 8
people living with HIV are unaware of their infection
40%
of people with HIV will develop peripheral neuropathy without treatment
25%
of people living with HIV worldwide still lack access to treatment
Our clinical team has over
120
years of combined clinical trial experience